Compare Freshworks Inc (FRSH) vs Summit Therapeutics Inc (SMMT) Price & Performance

Freshworks (FRSH) trades at $13.86, up 1.91% today, reflecting positive momentum following its Q2 2026 earnings beat. The stock exhibits a bullish technical trend with strong moving average signals, though the RSI suggests it may be approaching overbought territory. Fundamentally, the company has achieved a significant turnaround, posting its first GAAP profitable quarter in 2026 with revenue growth of 16% year-over-year, driven by strength in its employee experience portfolio and cost discipline.

The outlook is positive, supported by a 50% analyst buy rating and a consensus price target of $14.60, implying modest upside. Key opportunities include continued AI monetization and market share gains, while risks involve heightened competition in the SaaS sector and the need to sustain recent profitability improvements amid economic uncertainty.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.